Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects

World Journal of Gastroenterology

Volumn 20, Issue 36, 2014, Pages 12892-12899

  Merrett, Neil D ^a,b  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b Sydney South West Local Health District ^*  (Australia)

Author keywords

Adjuvant treatment; Gastrectomy; Gastric cancer; Human epidermal growth factor receptor; Multimodality; Neoadjuvant; Targeted therapy

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ASIA; AUSTRALIA AND NEW ZEALAND; CANCER SURGERY; CHEMORADIOTHERAPY; EUROPE; GENE TARGETING; HUMAN; MULTIMODALITY CANCER THERAPY; NORTH AMERICA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STOMACH CANCER; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CANCER STAGING; CLINICAL PRACTICE; COMORBIDITY; FORECASTING; GASTRECTOMY; HEALTH CARE DISPARITY; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RISK FACTOR; STANDARDS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TRENDS;

CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FORECASTING; GASTRECTOMY; GUIDELINE ADHERENCE; HEALTHCARE DISPARITIES; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84928387018     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i36.12892     Document Type: Review

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; (3): CD004064 [PMID: 20238327 DOI: 10.1002/14651858.CD004064.pub3]
3. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005; 81: 419-424 [PMID: 15998815]
4. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-816 [PMID: 15492562]
5. Yoo C, Kang Y. Review: Clinical Trial Outcomes: An update of adjuvant treatments for localized advanced gastric cancer. Clin Invest 2012; 2: 1101-1108 [DOI: 10.4155/cli.12.113]
6. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-1064 [PMID: 10533448 DOI: 10.1016/S0959-8049(99)00076-3]
7. GASTRIC (Global Advancement/Adjuvant Stomach Tumour Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737 [PMID: 20442389 DOI: 10.1001/jama.2010.534]
8. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984; 2: 1249-1254 [PMID: 6491703]
9. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-1312 [PMID: 7910321 DOI: 10.1016/S0140-6736(94)92464-3]
10. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 [PMID: 11547741 DOI: 10.1056/NEJMoa010187]
11. Berney CR, Merrett ND. Adjuvant chemoradiotherapy for gastric cancer. N Engl J Med 2002; 346: 210-211 [PMID: 11797726 DOI: 10.1056/NEJM200201173460316]
12. Jain VK, Cunningham D, Rao S. Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol 2011; 2: 334-342 [PMID: 23204792 DOI: 10.1007/s13193-012-0139-1]
13. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-2333 [PMID: 22585691 DOI: 10.1200/JCO.2011.36.7136]
14. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953]
15. Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU (ECF) before and after CI 5- FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 2011; 29: abstr 4003
16. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, Boot H, van Grieken NC, van de Velde CJ, Verheij M, Cats A. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011; 11: 329 [PMID: 21810227 DOI: 10.1186/1471-2407-11-329]
17. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
18. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721 [PMID: 21444866 DOI: 10.1200/JCO.2010.33.0597]
19. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447 [PMID: 8336183]
20. Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, Jolis L, Saigí E, Guasch I, Badia A, Boleda M. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815 [PMID: 10577853]
21. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, Medi F, Mercatelli A, Romano S, Siliani L, Tarquini R, Moretti R. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001; 84: 878-880 [PMID: 11286464 DOI: 10.1054/bjoc.2000.1472]
22. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820 [PMID: 17978289 DOI: 10.1056/NEJMoa072252]
23. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321 [PMID: 22226517 DOI: 10.1016/ S0140-6736(11)61873-4]
24. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393 [PMID: 22010012]
25. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077 [PMID: 15082726 DOI: 10.1200/JCO.2004.08.026]
26. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530 [PMID: 10188901 DOI: 10.1038/sj.bjc.6690243]
27. Maruyama K, Gunvén P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 1989; 210: 596-602 [PMID: 2818028 DOI: 10.1097/00000658-198911000-00005]
28. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995; 19: 532-536 [PMID: 7676695 DOI: 10.1007/BF00294714]
29. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-123 [PMID: 21573742]
30. Sano T, Yamamoto S, Sasako M. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol 2002; 32: 363-364 [PMID: 12417603 DOI: 10.1093/jjco/hyf085]
31. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, Scaglione D, Andreone D, Ponti A, Calvo F. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30: 303-308 [PMID: 15028313 DOI: 10.1016/j.ejso.2003.11.020]
32. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449 [PMID: 20409751 DOI: 10.1016/S1470-2045(10)70070-X]
33. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, Boot H, Putter H, Peeters KC, van de Velde CJ, Verheij M. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010; 28: 2430-2436 [PMID: 20368551 DOI: 10.1200/JCO.2009.26.9654]
34. Chen Y, Haveman J, Apostolou C, Chang D, Biankin AV, Merrett ND. Long-term survival in gastric cancer: The experiences of a single Australian centre. ANZ J Surg 2012; 82 Suppl 1: HP50P; 97
35. Schmidt B, Chang KK, Maduekwe UN, Look-Hong N, Rattner DW, Lauwers GY, Mullen JT, Yang HK, Yoon SS. D2 lymphadenectomy with surgical ex vivo dissection into node stations for gastric adenocarcinoma can be performed safely in Western patients and ensures optimal staging. Ann Surg Oncol 2013; 20: 2991-2999 [PMID: 23760588 DOI: 10.1245/s10434-013-3019-1]
36. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146 [PMID: 15657344 DOI: 10.1093/jnci/dji181]
37. Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol 2011; 6: 55 [PMID: 21615894 DOI: 10.1186/1748-717X-6-55]
38. Kang YK, Chang HM, Yook JH, Ryu MH, Park I, Min YJ, Zang DY, Kim GY, Yang DH, Jang SJ, Park YS, Lee JL, Kim TW, Oh ST, Park BK, Jung HY, Kim BS. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer 2013; 108: 1245-1251 [PMID: 23449357 DOI: 10.1038/bjc.2013.86]
39. Bejetta E, Floriani I, Bartolomeo MD, Labianca R, Landi L, Santoro A, Casaretti R, Pasquini E, Di Fabio F, Rondini E, Pinotti G, Bidoli P, Rosati G, Mambrini A, Ciarlo A, Cordio SS, Ricci S, Frassineti L, Di Costanzo F, Bochicchio AM. Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach (ITACA-S) trial: comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. J Clin Oncol 2012; 30 Suppl: Abstract LBA4001
40. Lee JL, Kang HJ, Kang YK, Ryu MH, Chang HM, Kim TW, Sohn HJ, Kim H, Lee JS. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol 2008; 61: 837-845 [PMID: 17579864 DOI: 10.1007/s00280-007-0541-5]
41. Kang YK, Ryoo BY, Chang HM, Zang DY, Kim TW, Yang DH, Jang SJ, Yook JH, Oh ST, Kim BS. Update of AMC 0101 study: A phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer (NCT00296322). J Clin Oncol 2012; 30 Suppl 4: Abstract 4
42. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.2011.36.2236]
43. Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson TJ, Petty RD, Plummer C, Allum WH, Blazeby JM, Griffin M, Cunningham D. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol 2013; 24: 702-709 [PMID: 23108952 DOI: 10.1093/annonc/mds533]
44. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
45. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes - a systematic review. Int J Cancer 2012; 130: 2845-2856 [PMID: 21780108 DOI: 10.1002/ijc.26292]
46. Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer 2012; 3: 137-144 [PMID: 22481979 DOI: 10.7150/jca.4090]
47. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991; 48: 668-671 [PMID: 1676988 DOI: 10.1002/ijc.2910480506]
48. Coupe NA, Karikios D, Chong S, Yap J, Ng W, Merrett N, Lin M. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Ann Nucl Med 2014; 28: 128-135 [PMID: 24297388]